• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    03 Feb 2025
    1575.80
    -0.15%
    Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure
    Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure
    NDTV Profit
    Cipla Medpro is responsible for the manufacturing, marketing, and supply of pharmaceutical products in South Africa.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    logo
    Divi's Laboratories Ltd.
    03 Feb 2025
    6200.00
    1.44%
    Divis Labs share surge 5% after profits rise 64% in Q3 results; know more
    Business Standard
    Divi's Laboratories share price slipped 4.60 per cent at Rs 5,881.15 a piece on the BSE in Monday's intraday trade after the pharmaceutical company's consolidated net profit for the third quarter
    Copy LinkShare onShare on Share on Share on
    Divi's Laboratories Ltd. is trading above its 200 day SMA of 6120.8
    logo
    Acutaas Chemicals Ltd.
    01 Feb 2025
    1458.10
    -0.88%
    Ami Organics extends rally on strong Q3 results; stock zooms 30% in 4 days
    Business Standard
    The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation of another CDMO contract in FY26E, Ami has strong revenue visibility.
    Copy LinkShare onShare on Share on Share on
    Acutaas Chemicals Ltd. has gained 23.59% in the last 6 Months
    logo
    Sun Pharmaceutical Industries Ltd.
    01 Feb 2025
    1656.00
    0.45%
    Sun Pharma Q3 Results Review Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'
    Sun Pharma Q3 Results Review Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'
    NDTV Profit
    Potential new launches of Deuruxolitinib and Nidlegy over next few quarters can help Sun Pharma sustain a double-digit growth in its specialty portfolio, adds the brokerage.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    Brokerages offer mixed views on Sun Pharma post steady Q3; buy, sell, hold?
    Business Standard | 01 Feb 2025 6 more
    Sun Pharma's FY25 R&D spend to fall below 7% of sales; Q3 revenue up 10.5%
    Business Line | 31 Jan 2025
    Sun Pharma Q3FY25 results: Net profit soars 15%, revenue up 10.5%
    Business Standard | 31 Jan 2025
    Sun Pharma Q3FY25 results: Net profit soars 15% to Rs 2,903.3 crore
    Business Standard | 31 Jan 2025
    Sun Pharma Q3 results: Net profit up 15% at Rs 2,905 cr on strong sales
    Business Standard | 31 Jan 2025
    Sun Pharmaceutical Q3 Results: Profit Rises 15%, Meets Estimates
    NDTV Profit | 31 Jan 2025
    Sun Pharma Q3 results: Net profit up 15% YoY to 2,903.4 crore, revenue up 10%
    livemint | 31 Jan 2025
    logo
    Pfizer Ltd.
    01 Feb 2025
    5107.50
    -1.64%
    Pfizer resolves conservative challenge to diversity fellowship program
    Pfizer resolves conservative challenge to diversity fellowship program
    livemint
    PFIZER-LAWSUIT/DIVERSITY (PIX):Pfizer resolves conservat
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading above its 200 day SMA of 4895.2
    Pfizer Q3 results: Net profit falls 2% to Rs 128 cr, revenue at Rs 538 cr
    Business Standard | 31 Jan 2025 1 more
    Pfizer Q3 Results: Profit Slips 2%, Revenue Down Marginally
    NDTV Profit | 31 Jan 2025
    logo
    AstraZeneca Pharma India Ltd.
    31 Jan 2025
    8934.50
    -1.54%
    AstraZeneca scraps $558 mn UK investment plans citing cut in govt support
    Business Standard
    The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    logo
    OneSource Specialty Pharma Ltd.
    31 Jan 2025
    1840.90
    -1.02%
    3 firms divest 6.8% stake in Onesource Specialty Pharma for Rs 1,202 crore
    Business Standard
    Three entities, including two promoters of Onesource Specialty Pharma, on Friday divested a 6.8 per cent stake in the company for Rs 1,202 crore through open market transactions. Tenshi Pharmaceuticals (Promoter) and Pronomz Ventures LLP (Promoter Group) and Medella Holdings Pte Ltd were the entities who have offloaded 77.66 lakh shares or 6.8 per cent stake in Bengaluru-based Onesource Specialty Pharma, as per the bulk deal data available on the NSE. The shares were disposed of in the price range of Rs 1,545-1,552.90 apiece, taking the combined value to Rs 1,202.23 crore. The promoters of the company divested a 3.4 per cent stake in the firm. After the latest transaction, the combined shareholding of promoter holding in Onesource Specialty Pharma has come down to 34.36 per cent from 37.77 per cent and Medella Holdings stake has declined to 0.8 per cent from 4.17 per cent. Meanwhile, Motilal Oswal Mutual Fund and CPT Research & Mgmt Co T/A CPT World Investors acquired 21.95 lakh .
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 4.95% of shares in last quarter. Total pledge stands at 25.01% of promoter holdings
    logo
    Jubilant Pharmova Ltd.
    31 Jan 2025
    1100.20
    -1.34%
    Jubilant Pharmova Q3 result: Profit rises 51% to Rs 101 cr on strong demand
    Business Standard
    Revenue rose 9 per cent to Rs 1,814 crore, lifted by the radiopharma segment's nearly 12 per cent growth this quarter
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.
    logo
    Ajanta Pharma Ltd.
    31 Jan 2025
    2544.60
    -0.15%
    Ajanta Pharmaceuticals Q3 Results 2025 on 31 Jan, 2025: profit rise by 10.88% YOY, profit at 232.88 crore and revenue at 1146.13 crore
    Ajanta Pharmaceuticals Q3 Results 2025 on 31 Jan, 2025: profit rise by 10.88% YOY, profit at 232.88 crore and revenue at 1146.13 crore
    livemint
    Ajanta Pharmaceuticals Q3 Results 2025 on 31 Jan, 2025: Revenue increased by 3.71% YoY & profit increased by 10.88% YoY, profit at 232.88 crore and revenue at 1146.13 crore.
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings
    Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore
    Business Standard | 30 Jan 2025 1 more
    Ajanta Pharma Q3 Results: Net Profit Up 11% At Rs 233 Crore
    NDTV Profit | 30 Jan 2025
    logo
    Hester Biosciences Ltd.
    30 Jan 2025
    2021.20
    -0.79%
    Hester Biosciences Q3 results: Net profit jumps 3-fold to Rs 11.41 cr
    Business Standard
    Hester Biosciences Ltd on Thursday reported a nearly three-fold jump in profit for the December quarter of 2024-25, mainly driven by foreign exchange gains. The company's profit after tax stood at Rs 11.41 crore in the October-December quarter of 2024-25 compared to Rs 4.02 crore in the year-ago period, an exchange filing said. Revenue from operations dropped by 6 per cent to Rs 63.22 crore for the third quarter of 2024-25 compared to Rs 66.98 crore in the year-ago period. The company recorded an unrealised foreign exchange gain of Rs 7.83 crore due to currency fluctuations. Revenue from animal healthcare division dropped 24 per cent while that from poultry segment rose by 12 per cent and from pet care more than doubled during the quarter. Rajiv Gandhi, CEO and MD of Hester Biosciences said, Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is
    Copy LinkShare onShare on Share on Share on
    Hester Biosciences Ltd. is trading below its 30 day SMA of 2034.6
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd